Real-world hematocrit control, burden of phlebotomy, and quality of life in patients with polycythemia vera treated with phlebotomy in the United States: results from a real-world survey
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by erythrocytosis. Therapeutic phlebotomy is widely used in PV care, aimed to lower hematocrit levels to <45%. This study aimed to assess the real-world burden of phlebotomy and patient quality of life (QoL). Data were drawn from the Adelphi Real World PV Disease Specific Programme™, a cross-sectional survey with retrospective data collection, in patients with PV and their treating physicians in the U.S. between August 2025 and February 2026. Thirty-nine physicians reported data for 160 patients; 97 had received a phlebotomy in the 12 months prior to the survey (23 frequent phlebotomy; 74 infrequent phlebotomy). Most (91.5%) had uncontrolled hematocrit levels, defined as ≥1 test ≥45%, and no significant association was found between hematocrit control and phlebotomy frequency. Fatigue was commonly reported as a phlebotomy side effect (69.1%) and as a symptom (19.6%), and the median PROMIS Fatigue score was 56.6 (48.1, 61.1). Median activity impairment on the WPAI was 30.0% (20.0, 65.0). Current treatments, including phlebotomy (with or without cytoreductive therapy), may not adequately control hematocrit or symptoms, and impair QoL. This highlights a need for treatment strategies that offer control over hematocrit and symptoms while improving QoL.
Authors
- MPH Katie Lewis
- Luis Hernandez (ORCID: https://orcid.org/0000-0003-1697-9084)
- Alicia Cerretani
- Amber Simpson (ORCID: https://orcid.org/0009-0005-2348-0400)
- Kristen Pettit
- Chloe Hall
- Angela Qi Fan
Publication Details
- Journal
- Figshare
- Published
- 2026-11-18
- DOI
- https://doi.org/10.6084/m9.figshare.35049871
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00